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Randomized, Double-Blind, Placebo-Controlled Trial:
FragXis Phase 2 Results
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Chin Y Wong6, Michael Rabbia7, Dennis Deptula8, Amy John9, Russell Kinch10, Philip Drewitt11,
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Luca Santarelli16, Jorge A Quiroz17 and FragXis Study Group
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Switzerland; 4Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Department of Pediatrics, University of California Davis,
School of Medicine, Sacramento, CA, USA; 5Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Department of
Psychiatry and Behavioral Sciences, University of California Davis, School of Medicine, Sacramento, CA, USA; 6Genentech Research and Early
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Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Welwyn, Welwyn, UK; 12Roche
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Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in
Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to
correct a broad range of phenotypes related to FXS. The early short-term clinical trials with mGluR5 NAMs, including basimglurant,
assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials. We evaluated
basimglurant, a potent and selective mGluR5 NAM, in a 12-week, double-blind, parallel-group study of 183 adults and adolescents (aged
14–50, mean 23.4 years) with FXS. Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of
basimglurant. The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and
Mood Scale (ADAMS) total score. All treatment arms showed marked behavioral improvements from baseline to week 12 with less
improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total
score. Treatment with basimglurant was overall well-tolerated. A higher incidence of adverse events classified as psychiatric disorders were
reported in patients treated with basimglurant, including three patients with hallucinations or psychosis. In this phase 2 clinical trial,
basimglurant did not demonstrate improvement over placebo. Evaluation of the overall risk-benefit in younger patient populations is an
important consideration for the design of potential further investigations of efficacy with this class of medications.
Neuropsychopharmacology (2018) 43, 503–512; doi:10.1038/npp.2017.177; published online 20 September 2017
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INTRODUCTION
Promising preclinical results have supported the hypothesis
that inhibition of the metabotropic glutamate receptor 5
(mGluR5) may improve symptoms of Fragile X syndrome
(FXS) (Bear et al, 2004; Hagerman et al, 2014). The ‘mGlu
receptor theory of Fragile X’ postulates that in the absence of
the Fragile X Mental Retardation Protein (FMRP), an RNA
binding protein that attenuates the translation of its target
transcripts (Li et al, 2001), there is excessive mGluR-
dependent protein synthesis which underlies the pathogen-
esis of FXS (Bear et al, 2004; Huber et al, 2002). Reduction of
mGluR5 activity by either genetic (Dolen et al, 2007) or
pharmacological (Bhakar et al, 2012; Michalon et al, 2012)
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means in Fmr1 KO mice has achieved the correction of
numerous FXS phenotypes, including biochemical, neuroa-
natomical, electrophysiological and synaptic plasticity altera-
tions, learning and memory impairment, audiogenic
seizures, and growth abnormalities. These data suggest that
the FXS phenotype is not an irreversible result of altered
brain development which collectively has prompted investi-
gations of the therapeutic potential of mGluR5 negative
allosteric modulators (NAMs) in humans.
In recent years, selective mGluR5 antagonists have been
studied in individuals with FXS in short-term clinical trials.
Fenobam (Porter et al, 2005), the first to be evaluated in a
single-dose open-label study of 12 male and female adults
with FXS (mean age 23.9 years), showed trends of
improvement in a prepulse inhibition deficit relative to
test–retest controls not receiving the drug (Berry-Kravis et al,
2009). Subsequently, a post-hoc analysis of a 12-week
crossover-study with mavoglurant (AFQ056) (Vranesic
et al, 2014) in 30 male adults (aged 18–35) with FXS
described maladaptive behavior reduction in a subset of
seven patients with full FMR1methylation (Jacquemont et al,
2011). These behavioral effects were not replicated in
subsequent 12-week, double-blind mavoglurant studies
enrolling male and female adolescents and adults in the
strata with either full or partial FMR1 methylation (Berry-
Kravis et al, 2016), which were conducted in parallel to this
basimglurant trial.
Basimglurant is a potent and selective mGluR5 NAM
(Jaeschke et al, 2015; Lindemann et al, 2015). In acute and
chronic rodent models of depression, basimglurant showed
robust antidepressant-like activity, wakefulness-promoting
effects and a consistent anxiolytic-like profile (Lindemann
et al, 2015). Moreover, basimglurant 1.5 mg showed an
antidepressant effect across secondary endpoints in patients
diagnosed with major depressive disorder, though the primary
outcome was not met (Quiroz et al, 2016). Taken together
with preclinical results from chronic treatment of Fmr1
knockout mice (Michalon et al, 2012) using CTEP
(Lindemann et al, 2011), a close chemical analogue of
basimglurant, these data were supportive of an initial
evaluation of basimglurant in a 6-week, randomized, double-
blind, placebo-controlled, safety and exploratory efficacy study
of 40 male and females with FXS (aged 18–49 years) treated
with placebo, or basimglurant at daily doses of 0.1, 0.5, 1.0, or
1.5 mg. In this trial, treatment with basimglurant was well
tolerated and, though not powered to detect a difference,
showed trends for clinical effects warranting further evalua-
tion using the same measures in a larger sample size
(unpublished data). Here, we report the results of the
randomized, double-blind, placebo-controlled phase 2 inves-
tigation of the safety and efficacy on behavioral symptoms
with basimglurant in adolescents and adults with FXS.
MATERIALS AND METHODS
Patients
Outpatients aged 14–50 with a confirmed FMR1 full
mutation at screening were eligible to participate. Enrolled
patients demonstrated a level of behavioral symptoms
(Aberrant Behavior Checklist (ABC) total ⩾ 20) as reported
by caregivers and were at least ‘mildly ill’ on the Clinical
Global Impression-Severity scale (CGI-S⩾ 3) based upon the
clinician’s overall assessment. The ABC entry score was
selected to ensure both a minimum level of symptoms and
adequate enrollment of females based upon the mean ABC
total score in patients with FXS (Sansone et al, 2012). Stable
doses of prescribed medications were permitted with the
exception of medications with a glutamatergic or GABAergic
mechanism of action. No new or changes to concomitant
treatments were permitted from screening to the final visit.
Adequate birth control was required for all patients during
the course of the trial.
Patients were excluded if they had received treatment with
another mGluR5 antagonist within 18 months prior to
screening or participated in a prior basimglurant trial. Other
exclusion criteria were any uncontrolled, unstable, clinically
significant psychiatric or medical conditions other than FXS,
including: seizures or a change in the anticonvulsant
pharmacotherapy in the previous 6 months; concurrent
symptoms or presumption of psychosis or euphoria; history
of catatonia, hallucinations or delusional thoughts; or history
of suicidal behaviors.
Either the patient or the parent/legal guardian provided
informed consent or assent prior to participation.
Study Design
This phase 2, double-blind, randomized, placebo-controlled,
12-week study of two doses of basimglurant (Supplementary
Figure 1) was conducted in accordance with the principles of
the ‘Declaration of Helsinki’ and Good Clinical Practice.
Approval of the study by the Independent Ethics Committee
or Institutional Review Board for each investigative center
was obtained before study start. An Independent Data
Monitoring Committee was convened to review available
unblinded safety data at regularly scheduled intervals.
After the screening period, patients underwent equal
randomization to either basimglurant 0.5 mg, basimglurant
1.5 mg, or matching placebo using an interactive voice
response system. Treatment allocation was stratified by sex
and by age group (adolescents 14–17 years old vs adults
18–50 years old) to ensure that approximately one-third of
enrolled patients were adolescents. The blinded study
medication was administered once daily in the morning
with food. Compliance was assessed by a caregiver-
completed medication diary as well as the return of all
unused study medication at each visit.
After consulting with health authorities, the protocol was
amended during study conduct to modify the primary
efficacy endpoint from the Anxiety Depression and Mood
Scale (ADAMS) social avoidance factor to ADAMS total
score. This change occurred without unblinding the study
and was not based upon blinded data review.
This clinical trial (FragXis, NP27936) is registered in www.
clinicaltrials.gov with the identifier NCT01517698. FragXis
was sponsored by Hoffmann La-Roche, Ltd, Switzerland
(http://www.roche-trials.com).
Assessments
Baseline demographic and caregiver information were
collected to better characterize enrolled patients including
the Wechsler Intelligence Scale for Children—Fourth Edition
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(WISC-IV) and the Autism Diagnostic Observation Schedule
(ADOS). A caregiver with knowledge of the patient’s
situation and level of impairment was identified upon
enrollment of patients and required to complete certain
rating scales. All identified caregivers watched a standardized
rater training video at the screening visit.
Efficacy assessments at the clinic visits (occurring every
3 weeks) were to be completed by the same person for the
study’s duration. The primary efficacy outcome was the
ADAMS total score, a 28-item caregiver-completed instrument
assessing aspects of anxiety, social interaction, compulsiveness,
communication, concentration, depression, and mood
(Esbensen et al, 2003). Higher scores indicate more severe
behavioral problems. The items are grouped into five factors
representing core behaviors and symptoms for individuals with
intellectual disability, including those with FXS.
For the secondary efficacy assessments, a number of
caregiver and clinician rated scales were used at clinic visits
to assess behaviors, functional skills, immediate memory, and
overall symptoms. The ABC total and two factor score
methods, based on a population of patients with intellectual
disabilities (Aman et al, 1985) and more recently in patients
with FXS (Sansone et al, 2012), as well as the Social
Responsiveness Scale (SRS) were used to measure symptoms
(Constantino et al, 2003). Additionally, the caregiver provided
a baseline description of the patient’s most troubling symptom
(MTS), including frequency, duration spent on it, and other
salient consequences. Caregivers then evaluated this behavior-
al symptom using a Visual Analog Scale (VAS) every 6 weeks.
For the analysis, each MTS description was coded using the
MedDRA classification of terms.
Clinicians were asked to evaluate all aspects of the patient’s
behavior and cognitive function using both the CGI Severity
of illness (CGI-S) and improvement (CGI-I) scales (Guy,
1976). The frequency of patients exhibiting clinical response
was defined by at least 25% improvement in the ABC total
score and a CGI-I score of 1 or 2. The remaining secondary
and exploratory assessments were conducted every 6 weeks.
This included the Vineland Adaptive Behavior Scale (VABS-
II) with the exception of the maladaptive behavior domain
(Sparrow et al, 2005), and the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS;
(Randolph et al, 1998)) List Learning and Story Memory
subtests based on prior studies where the subtests of
Immediate Memory were shown to be sufficiently reprodu-
cible in the FXS population (Berry-Kravis et al, 2006).
Additionally, exploratory caregiver-reported outcomes were
measured using the Caregiver Burden Inventory—Modified
(Caserta et al, 1996).
The safety and tolerability of basimglurant was assessed at
every clinic visit by monitoring vital signs, weight, Tanner
staging (in adolescents at baseline and week 12), menstrual
status (in females), clinical laboratory tests, and ECGs.
Spontaneously reported AEs and a clinical assessment of
suicidality were monitored weekly by phone calls or in clinic
visits.
Biomarkers Analysis
A whole blood sample was taken from every patient at
screening and analyzed via Southern Blot to confirm entry
criteria. Additional whole blood samples were taken at
baseline for analysis of DNA methylation status and CGG
repeat size, FMR1 mRNA and FMRP analyses (see
Supplementary Material).
Statistical Analyses
For the ADAMS total score, a closed testing procedure was
utilized which first tested the overall hypothesis at the two-
sided significance level α= 0.05 using Dunnett’s test, and
then tested each active arm vs placebo separately only if the
overall hypothesis H0 was rejected. The closed testing
procedure has a two-sided maximum family-wise error rate
of 0.05; therefore, no further adjustment for multiplicity was
required.
For each continuous efficacy endpoint, analysis was
performed using an MMRM model with the change from
baseline in the endpoint as the dependent variable, treatment,
visit, region, age group (adolescent vs adult) and sex as
independent effects, treatment-by-visit and age-by-sex inter-
action terms, and baseline value as the continuous covariate.
The sample size of 60 patients per group (a total of 180
patients for the three treatment groups) had been chosen to
obtain a power of approximately 80% at a two-sided
maximum, family-wise error rate of 0.05 in the testing
procedure. An effect size of 0.60 in at least one dose group at
week 12 (with an increasing treatment difference over the
period), and an overall dropout rate of 15%, were assumed.
The intent to treat (ITT) analysis population included all
randomized patients who received at least one dose of the
randomized study drug and was the primary analysis
population for all analyses of primary and secondary clinical
efficacy data. Subgroup analyses of the primary efficacy
variable were performed as defined by stratification factors at
randomization, clinically relevant baseline factors, and
selected biomarker subpopulations (defined using the
median biomarker values from the male patients) using an
MMRM model.
RESULTS
Patient Disposition and Demographics at Baseline
A total of 185 FX full mutation patients (151 male and 34
female) were randomized to basimglurant 0.5 mg, basim-
glurant 1.5 mg, or placebo at 39 centers in Argentina,
Canada, Chile, France, Great Britain, Mexico, Spain, Sweden
and the US between May 2012 and April 2014. Two patients
randomized to the 0.5 mg dose group withdrew from the
study prior to receiving any study treatment. Therefore, a
total of 183 patients received study treatment (ITT) and 167
completed the 12-week blinded treatment period. A higher
proportion of patients discontinued from the 12-week
treatment period in the basimglurant 1.5 mg dose group
(16.1%) than the 0.5 mg (8.6%) or placebo (1.6%) groups,
although the discontinuations related to adverse events (AE)
were similar in both basimglurant 1.5 and 0.5 mg dose
groups (9.7 and 8.6%, respectively; Supplementary Figure 2).
Patient demographics and baseline symptoms were gen-
erally well-matched for both the adolescent and adult
subpopulations (Table 1). Most patients had fluent speech;
nonverbal patients were not enrolled in the study. There
were some imbalances in the characterization of autism
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spectrum disorder (ASD) across treatment arms, with more
patients with fluent speech considered nonspectrum in the
placebo group than in both groups treated with basimglurant
(46 vs 25%). For those patients with phrase speech, all
patients randomized to placebo met autism spectrum
disorder criteria as compared to approximately 83% of those
randomized to basimglurant.
Previous and Concurrent Diseases and Treatments
The most frequent previous and concurrent conditions
reported per the MedDRA classification system were the
following psychiatric disorders: Anxiety (up to 27.0%),
attention deficit/hyperactivity disorder (up to 20.6%), and
aggression (up to 16.1%; see Supplementary Table 1). The
Table 1 Demographics and Baseline Disease Characteristics
Placebo (n= 63) Basimglurant 0.5 mg (n= 58) Basimglurant 1.5 mg (n= 62)
Age in years 23.7 (8.0) 22.4 (7.6) 24.2 (9.5)
Sex, n (%)
Male 51 (81%) 48 (83%) 50 (81%)
Female 12 (19%) 10 (17%) 12 (19%)
Weight at screening in kg 73.6 (18.8) 73.5 (15.9) 75.3 (16.3)
ADAMS total 30.7 (15.3) 26.7 (15.9) 25.6 (12.6)
ABC total 51.5 (27.0) 48.1 (30.7) 46.5 (27.0)
CGI-S 4.3 (1.1) 4.5 (1.0) 4.3 (1.1)
SRS T-Score 80.4 (13.8) 78.2 (11.7) 78.1 (12.9)
VABS-II Adaptive Behavior Composite Standard Scores 49.6 (20.1) 49.2 (25.9) 55.6 (34.6)
CBI-M 25.68 (16.90) 28.98 (19.59) 22.89 (13.30)
ADOS Module 2, n (%)
Autism 10 (77%) 11 (79%) 11 (73%)
Autism Spectrum Disorder 3 (23%) 1 (7%) 1 (7%)
Nonspectrum 0 2 (14%) 3 (20%)
ADOS Modules 3 and 4, n (%)
Autism 24 (50%) 25 (63%) 27 (64%)
Autism Spectrum Disorder 2 (4%) 5 (13%) 5 (12%)
Nonspectrum 22 (46%) 10 (25%) 10 (24%)
VAS most troublesome behavior coded term a
Anxiety disorders and symptomsb 10 (15.9%) 11 (19.0%) 11 (17.7%)
Behavior and socialization disturbancesc 18 (28.6%) 19 (32.8%) 16 (25.8%)
Changes in physical activity 1 (1.6%) 1 (1.7%) 2 (3.2%)
Cognitive and attention disorders 0 2 (3.4%) 2 (3.2%)
Communication disorders 10 (15.9%) 8 (13.8%) 11 (17.7%)
Developmental delayd 3 (4.8%) 6 (10.3) 3 (4.8%)
Mood disorder and disturbances NECe 4 (6.3%) 1 (1.7%) 3 (4.8%)
Social avoidant behavior and social phobia 14 (22.2%) 8 (13.8%) 11 (17.7%)
Not applicablef 2(3.2%) 1 (1.7%) 1 (1.6%)
Otherg 1 (1.6%) 1 (1.7%) 2 (3.2%)
A higher ADAMS, ABC, CGI-S, SRS and CBI-M score indicates more severe behavioral symptoms. A lower VABS-II score indicates more impaired adaptive behavior. All
data are presented as mean (SD) unless specified.
aMost troubling symptom coded term is the MedDRA Higher Level Group Term unless otherwise specified.
bAnxiety disorders and symptoms excludes social phobia.
cBehavior and socialization disturbances was used in place of the Higher Level Group Term and includes impulsive behavior and sexually inappropriate behavior and
excludes social avoidant behavior.
dDevelopmental delay was used in place of the Higher Level Group Term.
eMood disorders and disturbances NEC includes depression.
fNot applicable includes no specific behavior concern or assessment not completed.
gOther includes enuresis, perseveration, autism, and eating disorder symptom NOS.
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use of psychotropic medicine was similar across treatment
groups, with the most common classes being CNS stimulants
(up to 20.6%), antipsychotic and antimanic agents (up to
25.9%), selective serotonin re-uptake inhibitors (up to 27.0%)
and tetracyclines (ie minocycline, up to 10.3%; see
Supplementary Table 2).
Caregiver Characteristics and Baseline Observations
Nearly all caregivers were a parent of the patient (96%), and
74% reported spending over 40 h each week interacting with
the patient (see Supplementary Table 3). The common
caregiver-reported MTS used for the VAS were anxiety
disorders and symptoms, behavior and socialization
disturbances, communication disorders and disturbances,
and social avoidant behavior/social phobia (examples in
Table 1). Additionally, the level of caregiver burden at
baseline was similar across groups as assessed by the CBI-M
(Table 1).
Effect of Basimglurant on the ADAMs
In the primary endpoint analysis for the ADAMS total
change from baseline to week 12, both basimglurant
treatment groups showed no improvement over placebo
(Figure 1). In fact, significantly greater reductions from
baseline were observed in the placebo group compared to the
basimglurant 0.5 mg group (difference from placebo (90%
confidence interval) of 4.43 (1.43–7.43), adjusted p= 0.030)
but not the basimglurant 1.5 mg group (difference from
placebo of 2.00 (−1.00–5.00), adjusted p= 0.271) (Table 2).
ADAMS total score results were prospectively analyzed in
separate subgroup analyses. In all analyses, basimglurant
showed no improvement over placebo in any subgroups
(Table 2).
Effects of Basimglurant on Secondary Measures
Similarly, in the analyses of the secondary endpoints, all
treatment groups improved but basimglurant did not
demonstrate any benefit over placebo at Week 12 in the
ABC total and factor scores, SRS T-score, VAS, VABS-II
Adaptive Behavior Composite standard score (Table 2) or
ADAMS factor scores (Supplementary Table 4). Treatment
with basimglurant did not show improvement over placebo
on the CGI-S and CGI-I. Of note, placebo had a greater
improvement over the basimglurant 0.5 mg group in the
CGI-I and a greater improvement over both basimglurant
dose groups in the SRS T-Score (po0.05, Table 2).
Correspondingly, more responders at week 12 were in the
placebo group (23.81%) as compared to basimglurant 0.5 mg
(13.79%, p= 0.174) and 1.5 mg (17.74%, p= 0.510) groups
(Table 2).
Biomarker Subgroup Analysis of Study Patients
Baseline measures for methylation status of the FMR1 gene,
mRNA and FMRP showed considerable heterogeneity in the
study population (Figure 2). Correlations were observed
between FMR1 methylation status and mRNA levels
(Pearson correlation coefficient (r) of − 0.74), and between
FMR1 methylation status and FMRP levels (r=− 0.64) but
not between mRNA and FMRP concentrations (r= 0.39;
po0.001 for all paired data sets).
The relationship of biomarker subgroups and the effects of
basimglurant were also explored. Biomarker positive was
defined by FMR1 methylation greater than 73.95% of the
analyzed methylation sites, mRNA ΔCT count greater than
1.975, or FMRP concentrations less than 0.146 pM. The
analysis showed that both biomarker-positive and -negative
subgroups did not differ significantly between placebo and
basimglurant in the assessment of change from baseline to
week 12 for the ADAMS total score (Table 2). In the FMR1
methylation negative (o73.95%) subgroup, patients who
were randomized to the placebo arm improved significantly
(p= 0.019) compared to patients in the basimglurant 0.5 mg
dose arm. This improvement may be driven by the change in
ADAMS total scores from the female patients in the
placebo arm.
Safety and Tolerability of Basimglurant
Approximately two-thirds of patients (122 of 183) experi-
enced at least one AE during the study. Of the most common
AEs (45% incidence; Table 3), those classified as psychiatric
disorders had a higher incidence in patients treated with
basimglurant 0.5 mg (21 AEs in 24.1% of patients) and
basimglurant 1.5 mg (61 AEs in 40.3% of patients) compared
to those given placebo (12 AEs in 14.3% of patients). Most
AEs were considered mild to moderate in severity. All of the
severe AEs occurred in 4 adults in the basimglurant 1.5 mg
dose (n= 3) and 0.5 mg (n= 1) groups and were mainly
psychiatric disorders. One serious adverse event of fecaloma
(extreme form of fecal impaction) requiring overnight
hospitalization was reported in the placebo group but the
patient continued in the study.
A similar number of patients on basimglurant 0.5 and
1.5 mg discontinued due to AEs with the most frequent
events being psychiatric disorders (basimglurant 0.5 mg,
n= 4 (6.9%) and basimglurant 1.5 mg, n= 4 (6.5%) vs
placebo, n= 1 (1.6%)). Two adult male patients receiving
basimglurant 1.5 mg experienced hallucinations; one of the
two events resolved during the study. One patient from the
basimglurant 0.5 mg group had an event of ‘moderate
psychotic disorder’ which was resolving at the end of the
study. For all three patients, the event occurred with or was
preceded by adverse events of insomnia or poor sleep, and all
Figure 1 Change from baseline in ADAMS Total scores at each visit
(ITT). A decrease in the ADAMS total score indicates improvement. Both
basimglurant treatment groups showed no improvement over placebo.
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three patients were discontinued from study treatment
immediately after the AE was observed.
Overall, no clinically relevant changes in mean laboratory
parameters, vital signs, ECG, menstrual status (in females),
or physical exams including weight and sexual maturation
(Tanner staging and hormones related to sexual maturation
in adolescents) indicative of any treatment-emergent effect
were noted during the study.
DISCUSSION
This phase 2 study was the first to evaluate the efficacy of
basimglurant, a potent and selective mGluR5 NAM, in
adolescents and adults with FXS. The primary endpoint, the
ADAMS total, measured social avoidance, manic/hyperactive
behavior and other behavioral symptoms, with the largest
improvement in the placebo group, followed by
improvement in the basimglurant 0.5 and 1.5 mg arms,
respectively. Additionally, analyses of the secondary efficacy
endpoints evaluating several behavioral components, func-
tioning, and overall severity of illness showed similar
directional improvements for placebo over the active
treatment groups. The replication of these negative findings
with those seen in the 12-week, double-blind mavoglurant
studies, though conducted in parallel with this basimglurant
study, is salient given several design differences including
their implementation of a placebo run-in phase, stratification
by methylation status and up-titration dosing strategy
(Berry-Kravis et al, 2016).
The lack of a measureable therapeutic effect in this study
has several potential contributing factors, including endpoint
selection, study design and implementation, placebo re-
sponse, subgroup heterogeneity and ultimately the translat-
ability of preclinical findings into a clinical population. The
Table 2 Change from Baseline at Week 12 for all Efficacy Endpoints
Assessment (analysis method) Placebo Basimglurant 0.5 mg Basimglurant 1.5 mg
n Mean (SEM) n Mean (SEM) n Mean (SEM)
ADAMS Total Score (MMRM) 61 − 10.63 (1.49)a 51 − 6.20 (1.69) 51 − 8.63 (1.55)
Demographic subgroup analysis
Adolescents (o18 years) 21 − 9.4 (2.3) 17 − 4.4 (2.7) 18 − 8.4 (2.5)
Adults (⩾ 18 years) 40 − 11.8 (1.8) 34 − 7.7 (1.9) 33 − 9.2 (1.9)
Males 50 − 9.1 (1.5) 43 − 6.3 (1.7) 42 − 9.0 (1.6)
Females 11 − 18.9 (2.9) 8 − 6.8 (3.5) 9 − 8.4 (3.1)
Antipsychotic use 13 − 4.0 (2.8) 12 0.0 (2.8) 10 − 4.4 (2.9)
No antipsychotic use 48 − 12.0 (1.5) 39 − 7.6 (1.8) 41 − 9.3 (1.6)
Biomarker subgroup analyses
Methylation positive (⩾ 73.95%) 22 − 9.3 (2.3) 23 − 6.7 (2.3) 23 − 9.2 (2.3)
Methylation negative (o73.95%) 39 − 11.5 (1.9)a 28 − 5.8 (2.2) 28 − 8.7 (1.9)
mRNA Δ count positive (⩾ 1.975) 25 − 7.2 (3.2) 22 − 3.4 (3.4) 23 − 5.6 (3.0)
mRNA Δ count negative (o1.975) 35 − 11.6 (1.9) 28 − 6.3 (2.1) 27 − 9.5 (2.0)
FMRP positive (⩽ 0.146 pM) 18 − 7.1 (2.3) 19 − 6.1 (2.4) 22 − 8.1 (2.3)
FMRP negative (40.146 pM) 34 − 13.4 (2.2) 21 − 5.6 (2.8) 25 − 9.4 (2.3)
ABC Total (MMRM) 62 − 16.26 (2.81) 51 − 10.46 (3.11) 51 − 11.53 (2.91)
CGI-S (Wilcoxon-LOCF) 62 − 0.26 (0.07) 58 − 0.26 (0.08) 56 − 0.27 (0.10)
CGI-I (Wilcoxon-LOCF) 62 3.06 (0.11)a 58 3.47 (0.12) 57 3.39 (0.16)
Clinical Response Rate (Fisher-LOCF)b 63 23.81% 58 13.79% 62 17.74%
SRS T-Score (MMRM) 62 − 8.25 (1.44)c 53 − 3.65 (1.58) 52 − 4.65 (1.48)
RBANS Immediate Memory (ANCOVA-LOCF) 59 0.69 (1.52) 50 1.37 (1.67) 46 0.87 (1.57)
VABS-II Composite Standard Score (MMRM) 47 3.93 (2.57) 40 1.70 (2.80) 41 2.71 (2.50)
VAS MTS (Wilcoxon-LOCF) 62 − 20.35 (4.03) 56 − 12.45 (3.34) 54 − 16.11 (4.20)
A decrease in ADAMS, ABC, CGI-S, CGI-I, SRS, and VAS scores indicates improvement. An increase in the RBANS and VABS-II score indicates improvement. Values are
least square mean (SEM).
Analyses conducted were based upon the assessment and include Mixed Effect Model Repeated Measures (MMRM), Wilcoxon-Last Observation Carried Forward
(LOCF), Fisher-LOCF, and analysis of covariance (ANCOVA)-LOCF, all with standard error of the mean (SEM).
ap⩽ 0.05 compared to basimglurant 0.5 mg.
bClinical response defined as a composite of improvement in ABC Total Score of 25% or more and of a CGI-I score of either 1 or 2.
cp⩽ 0.05 compared to basimglurant 0.5 and 1.5 mg.
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selection of a primary efficacy endpoint in a disorder with no
prior clinical precedence for specific behaviors or symptoms
that may be modified by a pharmacological intervention has
proven extremely difficult. The Fragile X Outcome Measures
Working Group, an NIH-supported collaboration, con-
cluded that no single endpoint or set of endpoints could be
identified that met all criteria as an optimal measure for
studies investigating a treatment effect (Berry-Kravis et al,
2013). Notwithstanding, promising outcome measurements
included the ADAMS and ABC, which have some overlap in
their underlying behavioral construct, SRS, and RBANS; all
of which were explored in this study. Though the ABC scale
has some regulatory approval precedence in autism and was
selected as the primary measure in both mavoglurant and
arbaclofen trials in FXS, we selected the ADAMS total as the
primary outcome measure for this study based on both the
prominence of social anxiety, hyperactivity and mood-
related symptoms in the phenotype of patients with FXS,
as well as trends of improvement observed in our initial
study in adults with the disorder. Of note, our study data are
consistent with the negative mavoglurant results in that no
difference from placebo was detected on the ABC total or
factors, CGI-I, and SRS total score. It is still possible that the
scope of the assessments used were not comprehensive
enough to detect early treatment effects, especially since
behavioral patterns are typically developed during the
lifetime of an individual based upon environmental influ-
ences. Therefore future studies should also place an
emphasis on novel, or more sensitive endpoints capturing
relevant improvements in core domains of FXS, including
cognition. In particular, combining pharmacologic interven-
tions with cognitive-behavioral therapies in patients with
FXS may elicit broader responses that could be captured by
these or alternative endpoints.
Several factors in the protocol design and data analysis
were implemented to minimize variability, subjectivity, and
potential placebo effect. The primary outcome and behavior-
al entry criterion (ADAMS and ABC total score, respectively)
were selected to be different with the objective of minimizing
baseline score inflation. Moreover, selected outcome
Figure 2 Biomarker analysis of FMR1 promoter methylation, FMR1
mRNA and FMRP in study patients. The figure shows the frequency
distribution of biomarker data. Data of patients were distributed over 50
bins and frequency of appearance is depicted on the Y-axis. Male-derived
samples are in solid black and Female in blue bars. (a) Levels of FMRP in
whole blood in pM. Most of the male patients had no detectable levels of
FMRP in the blood (0 pM). (b) Levels of FMR1 mRNA expressed as delta
CT values. Note that delta Ct values over 6 are not considered to represent
quantifiable levels of mRNA but rather unspecific noise as judged by the CP
curves. (c) Methylation of the FMR1 promoter expressed in percent
methylation of analyzed methylation sites.
Table 3 Adverse Events with an Incidence of ⩾ 5% in at Least One
Treatment Arm
Placebo
(n= 63)
Basimglurant
0.5 mg (n=58)
Basimglurant
1.5 mg (n= 62)
Overall total
number of AEs
112 96 155
Total patients with
at least one AE, n
(%)
40 (63.5%) 37 (63.8%) 45 (72.6%)
Nasopharyngitis 11 (17.5%) 9 (15.5%) 6 (9.7%)
Headache 10 (15.9%) 4 (6.9%) 10 (16.1%)
Vomiting 5 (7.9%) 3 (5.2%) 7 (11.3%)
Upper respiratory
tract infection
4 (6.3%) 1 (1.7%) 6 (9.7%)
Anxiety 1 (1.6%) 2 (3.4%) 6 (9.7%)
Aggression 1 (1.6%) 5 (8.6%) 5 (8.1%)
Insomnia 1 (1.6%) 0 5 (8.1%)
Diarrhea 3 (4.8%) 4 (6.9%) 2 (3.2%)
Upper abdominal
pain
4 (6.3%) 2 (3.4%) 0
Agitation 2 (3.2%) 0 4 (6.5%)
Dizziness 1 (1.6%) 1 (1.7%) 4 (6.5%)
Irritability 1 (1.6%) 3 (5.2%) 3 (4.8%)
All adverse events (MedDRA preferred term) were reported by the safety
population during the study treatment and follow-up periods. Multiple
occurrences of the same AE in an individual were counted only once. For
frequency counts in the ‘Total number of AEs’ row, multiple occurrences of the
same AE in an individual are counted separately. The safety population consisted
of all patients who had received at least one dose of study medication.
Effect of basimglurant in individuals with FXS
EA Youssef et al
509
Neuropsychopharmacology
measures were assessed by the caregiver (ADAMS, ABC,
SRS, VAS) and clinician (CGI-S, CGI-I, RBANS, VABS-II) to
capture potential improvement irrespective of the observer.
Lastly, the same rater was required to conduct both the
baseline and week 12 assessments, and where this did not
occur, the per protocol analysis removed patient data with
protocol violations. Despite these measures, none of these
analyses altered the overall study results.
In this trial, all treatment arms improved, with patients in
the basimglurant groups having less improvement than
placebo. These changes, including the improvement in the
placebo arm, may be at least partially explained by the higher
frequency of interactions between patients and caregivers
with the research staff during the study (Rutherford et al,
2011) or a degree of expectation bias, as cited in secretin
treatment trials in individuals with autism (Volkmar, 1999)
and suggested based upon the substantial improvements
during the placebo run-in phase in the mavoglurant trials
(Berry-Kravis et al, 2016). Nevertheless, the larger placebo
improvement cannot entirely account for the results
observed, and consideration should be given to the relatively
smaller improvement observed in the basimglurant
groups, which could be better explained by the level of
behaviorally based adverse events, such as anxiety, aggres-
sion, agitation, and irritability, associated with the active
treatment arms.
Pre-specified subgroup exploratory analyses including the
stratification factors for age and sex were performed, with
similar negative results. Based upon the neurodevelopmental
nature of FXS and the mechanism of action of basimglurant
it has been hypothesized that mGluR5 treatment in younger
patients may help reverse deficits and prevent further insult
caused by the lack of FMRP during brain development and
maturation (Krueger and Bear, 2011). In our analysis which
was divided by age (adolescents 14–17 and adults 18–50
years), no improvement over placebo was seen in either
subgroup. Nonetheless, it is still possible that pharmacolo-
gical interventions might be more efficacious at very early
ages, when a larger degree of neuronal plasticity-related
development is still occurring. Owing to the different
phenotypic presentation across sexes, we also analyzed the
treatment effect in both subpopulations. In this study, no sex
differences in clinical responses were detected although the
small number of females enrolled makes this finding
inconclusive. Additionally, the ADOS was used as a
demographic parameter for ASD severity, but given the
imbalance of ASD across treatment arms, a subgroup
analysis was not conducted. Based on the scope of subgroup
analyses and the overall low proportion of responders (ABC
and CGI composite) that remained higher in the placebo
group than either basimglurant group, the overall inter-
pretation of the results would not be anticipated to be
different.
It has been previously reported in a small subgroup of
patients that expression of FMR1 mRNA and methylation of
the promoter region of the FMR1 gene may influence the
response to mGluR5 NAM treatment (Jacquemont et al,
2011). We could not confirm this finding by analyzing FMR1
methylation, FMR1 mRNA, and FMRP levels in whole blood
samples and performing the corresponding population
subgroup analyses using the mean of the distribution for
all three biomarker parameters. Correlations between FMR1
methylation and FMR1 mRNA levels, as well as FMR1
methylation and FMRP levels, however, confirm the
biological validity of the biomarkers employed. While the
mavoglurant phase 2 trials stratified individuals based on the
extent of FMR1 methylation, the definition of complete and
partial methylation was not provided to allow comparison
with our biomarker analysis. Nevertheless, our exploratory
subgroup analyses did not find any biomarker to be
predictive of basimglurant treatment response and
confirm the negative mavoglurant results (Berry-Kravis
et al, 2016).
The results in this study contrast the preclinical data
obtained with mGluR5 antagonists in Fmr1 KO mice. While
the Fmr1 KO mice replicate the primary molecular
determinant of FXS, that is, the lack of FMRP expression,
they fall short of replicating the human disease in its full
complexity, especially with respect to DNA methylation,
X-chromosomal and somatic mosaicism, as well as modifier
genes. Nonetheless, given the breadth of phenotypes
corrected with different mGlu5 NAM’s in Fmr1 KO mice,
and consistent results obtained from multiple laboratories,
the complete lack of translation of the preclinical findings to
the clinical outcomes does warrant further investigation
(Scharf et al, 2015).
In this phase 2 clinical trial, basimglurant was found
to be ineffective in the treatment of adults and adolescents
with FXS relative to placebo. Consistent with other
basimglurant studies, treatment at doses of 0.5 and 1.5 mg
once a day was generally well tolerated; however, a higher
incidence of adverse events classified as psychiatric disorders
were reported in patients treated with basimglurant
compared to those receiving placebo. It is possible that
longer treatment durations utilizing more sensitive outcome
measures and/or focusing on cognitive and learning
paradigms in a younger group of individuals may detect
previously unnoticed treatment effects of mGluR5 NAM’s in
FXS patients.
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